Divi's Laboratories Ltd
Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the company, through its Custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.(Source : 201903 Annual Report Page No: 91)
- Market Cap ₹ 89,280 Cr.
- Current Price ₹ 3,363
- High / Low ₹ 3,915 / 1,626
- Stock P/E 47.7
- Book Value ₹ 314
- Dividend Yield 0.48 %
- ROCE 25.2 %
- ROE 19.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 30.84%
- Company's median sales growth is 18.06% of last 10 years
Cons
- Stock is trading at 10.73 times its book value
- The company has delivered a poor sales growth of 11.61% over past five years.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
821 | 995 | 1,324 | 1,360 | 1,267 | 1,163 | 1,446 | 1,396 | 1,390 | 1,730 | 1,749 | 1,701 | |
501 | 643 | 802 | 827 | 851 | 776 | 955 | 902 | 945 | 1,030 | 1,008 | 1,010 | |
Operating Profit | 319 | 352 | 521 | 533 | 416 | 387 | 491 | 494 | 444 | 700 | 741 | 691 |
OPM % | 39% | 35% | 39% | 39% | 33% | 33% | 34% | 35% | 32% | 40% | 42% | 41% |
Other Income | 11 | 49 | 80 | 34 | 41 | 30 | 47 | 42 | 77 | 17 | 14 | 19 |
Interest | 1 | 1 | 0 | 3 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 |
Depreciation | 45 | 42 | 42 | 42 | 42 | 44 | 46 | 47 | 50 | 56 | 61 | 68 |
Profit before tax | 286 | 359 | 559 | 522 | 415 | 373 | 488 | 487 | 471 | 661 | 693 | 642 |
Tax % | 19% | 25% | 28% | 25% | 30% | 27% | 27% | 26% | 18% | 26% | 25% | 27% |
Net Profit | 231 | 268 | 404 | 389 | 292 | 272 | 357 | 359 | 388 | 492 | 520 | 471 |
EPS in Rs | 8.72 | 10.08 | 15.21 | 14.67 | 11.00 | 10.26 | 13.44 | 13.53 | 14.62 | 18.54 | 19.57 | 17.73 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,180 | 942 | 1,317 | 1,864 | 2,145 | 2,532 | 3,115 | 3,776 | 4,064 | 3,891 | 4,946 | 5,394 | 6,571 | |
699 | 536 | 816 | 1,173 | 1,329 | 1,514 | 1,942 | 2,354 | 2,616 | 2,623 | 3,073 | 3,571 | 3,994 | |
Operating Profit | 481 | 405 | 501 | 691 | 816 | 1,018 | 1,173 | 1,422 | 1,449 | 1,269 | 1,873 | 1,823 | 2,577 |
OPM % | 41% | 43% | 38% | 37% | 38% | 40% | 38% | 38% | 36% | 33% | 38% | 34% | 39% |
Other Income | 22 | 34 | 27 | 56 | 45 | 68 | 38 | 94 | 73 | 107 | 155 | 190 | 127 |
Interest | 7 | 3 | 2 | 5 | 3 | 3 | 3 | 5 | 3 | 2 | 5 | 7 | 1 |
Depreciation | 48 | 51 | 53 | 62 | 77 | 92 | 136 | 118 | 123 | 142 | 169 | 186 | 235 |
Profit before tax | 448 | 385 | 472 | 681 | 781 | 991 | 1,072 | 1,393 | 1,395 | 1,231 | 1,855 | 1,819 | 2,468 |
Tax % | 7% | 12% | 9% | 22% | 23% | 22% | 21% | 19% | 24% | 29% | 27% | 24% | |
Net Profit | 417 | 340 | 429 | 533 | 602 | 773 | 852 | 1,126 | 1,060 | 877 | 1,353 | 1,377 | 1,870 |
EPS in Rs | 16.09 | 12.88 | 16.19 | 20.09 | 22.67 | 29.13 | 32.07 | 42.41 | 39.95 | 33.04 | 50.96 | 51.85 | 70.46 |
Dividend Payout % | 9% | 23% | 31% | 32% | 33% | 34% | 31% | 24% | 25% | 30% | 31% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 12% |
3 Years: | 10% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 10% |
3 Years: | 9% |
TTM: | 46% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 28% |
3 Years: | 49% |
1 Year: | 60% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 21% |
3 Years: | 19% |
Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 26 | 27 | 27 | 27 | 27 | 27 | 53 | 53 | 53 | 53 | 53 | 53 | |
Reserves | 1,228 | 1,491 | 1,771 | 2,105 | 2,474 | 2,937 | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 8,270 |
Borrowings | 53 | 33 | 23 | 55 | 33 | 18 | 27 | 42 | 36 | 63 | 106 | 39 | 5 |
254 | 308 | 454 | 570 | 605 | 729 | 883 | 562 | 762 | 797 | 973 | 1,183 | 1,196 | |
Total Liabilities | 1,548 | 1,859 | 2,275 | 2,757 | 3,139 | 3,710 | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 9,524 |
590 | 590 | 590 | 738 | 909 | 1,222 | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,495 | |
CWIP | 20 | 24 | 104 | 182 | 303 | 144 | 218 | 264 | 444 | 120 | 492 | 920 | 499 |
Investments | 172 | 441 | 526 | 477 | 408 | 502 | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 |
767 | 804 | 1,055 | 1,359 | 1,519 | 1,842 | 2,145 | 2,392 | 2,521 | 2,780 | 3,511 | 3,858 | 5,530 | |
Total Assets | 1,548 | 1,859 | 2,275 | 2,757 | 3,139 | 3,710 | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 9,524 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
301 | 369 | 327 | 338 | 480 | 557 | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | |
-217 | -317 | -221 | -204 | -255 | -305 | -521 | -406 | -1,140 | -478 | -685 | -83 | |
-82 | -48 | -104 | -131 | -231 | -248 | -303 | -631 | 2 | -314 | -246 | -1,091 | |
Net Cash Flow | 1 | 5 | 1 | 3 | -5 | 3 | 3 | 0 | 13 | -17 | 23 | 41 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 41% | 27% | 28% | 34% | 33% | 36% | 33% | 36% | 29% | 22% | 29% | 25% |
Debtor Days | 82 | 87 | 101 | 97 | 87 | 104 | 87 | 85 | 81 | 95 | 86 | 96 |
Inventory Turnover | 1.35 | 0.76 | 1.09 | 1.38 | 1.23 | 1.20 | 1.32 | 1.42 | 1.40 | 1.35 | 1.35 | 1.34 |
Documents
Add documentRecent announcements
- Outcome Of Board Meeting Held On 06 February, 2021 6 Feb
- Schedule Of Earnings Conference Call Q3 FY21 29 Jan
- Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended 31 December, 2020. 23 Jan
- Shareholding for the Period Ended December 31, 2020 7 Jan
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jan
View all
Annual reports
- Financial Year 2020 from bse
- Financial Year 2019 from bse
- Financial Year 2018 from bse
- Financial Year 2017 from bse
- Financial Year 2016 from bse
- Financial Year 2015 from bse
- Financial Year 2014 from bse
- Financial Year 2013 from bse
- Financial Year 2013 from nse
- Financial Year 2012 from bse
- Financial Year 2012 from nse
- Financial Year 2011 from bse
- Financial Year 2011 from nse
- Financial Year 2010 from bse
- Financial Year 2010 from nse
- Financial Year 2009 from nse